Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 32, Issue 3-4, 2005, Pages 485-500

  Gopalakrishnan, Mathangi ^a   Suarez, Sandra ^b   Hickey, Anthony J ^c   Gobburu, Jogarao V S ^c  

^a Center for Drug Evaluation and Research ^*

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Glucose; HMAP; Indirect response model; Insulin; Population pharmacokinetic pharmacodynamic modeling

Indexed keywords

GLUCOSE; HYDROXYMETHYLAMINOPROPIONIC ACID; INSULIN; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; GLUCOSE TRANSPORT; LITERATURE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, INHALATION; ALANINE; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MODELS, BIOLOGICAL; RATS; RESPIRATORY SYSTEM;

EID: 28444458088     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-005-0008-4     Document Type: Article

References (34)

1. J.R. White Jr. R.K. Campbell I. Hirsch 1997 Insulin analogues: new agents for improving glycemic control Postgrad. Med. 101 58 60 63-5, 70
2. G.A. Brunner B. Balent M. Ellmerer L. Schaupp A. Siebenhofer J.H Jendle J. Okikawa T.R. Pieber 2001 Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients Diabetologia 44 305 8
3. L. Heinemann T. Traut T. Heise 1997 Time-action profile of inhaled insulin Diabet. Med. 14 63 72
4. J.S. Skyler W.T. Cefalu I.A. Kourides W.H. Landschulz C.C Balagtas S.L. Cheng R.A. Gelfand 2001 Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study Lancet 357 331 5
5. W.T. Cefalu J.S. Skyler I.A. Kourides W.H. Landschulz C.C Balagtas S. Cheng R.A. Gelfand 2001 Inhaled human insulin treatment in patients with type 2 diabetes mellitus Ann. Intern. Med. 134 203 7
6. F. Johansson E. Hjertberg S. Eirefelt A. Tronde U. Hultkvist Bengtsson 2002 Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate Eur. J. Pharm. Sci. 17 63 71
7. M. Dahlback S. Eirefelt K. Backstrom P. Larsson L.O. Almer P Wollmer B. Jonson 2002 Enhanced insulin absorption in the rabbit airways and lung by sodium dioctyl sulfosuccinate J. Aerosol Med. 15 27 36
8. Z. Shen Q. Zhang S. Wei T. Nagai 1999 Proteolytic enzymes as a limitation for pulmonary absorption of insulin: in vitro and in vivo investigations Int. J. Pharm. 192 115 121
9. A. Leone-Bay K.K. Ho R. Agarwal R.A. Baughman K. Chaudhary F DeMorin L. Genoble C. [tmp] McInnes C. Lercara S. Milstein D O'Toole D. Sarubbi B. Variano D.R. Paton 1996 4-[4-[(2-Hydroxybenzoyl)amino]phenyl]butyric acid as a novel oral delivery agent for recombinant human growth hormone J. Med. Chem. 39 2571 8
10. A. Leone-Bay N. Santiago D. Achan K. Chaudhary F. DeMorin L Falzarano S. Haas S. Kalbag D. Kaplan H. Leipold 1995 N-acylated alpha-amino acids as novel oral delivery agents for proteins J. Med Chem. 38 4263 9
11. S.J. Milstein H. Leipold D. Sarubbi A. Leone-Bay G.M. Mlynek J.R. Robinson M. Kasimova E. Freire 1998 Partially unfolded proteins efficiently penetrate cell membranes-implications for oral drug delivery J Control. Release 53 259 67
12. S. Suarez L. Garcia-Contreras D. Sarubbi E. Flanders D O'Toole J. Smart A.J. Hickey 2001 Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats Pharm Res. 18 1677 84
13. N.H. Holford R.J. Ambros K. Stoeckel 1992 Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil J. Pharmacokinet. Biopharm. 20 421 42
14. L. B. S. S.L Beal, editors. NONMEM user's guide. San Francisco, CA:NONMEM Project Group, University of California, 1992
15. N.L. Dayneka V. Garg W.J. Jusko 1993 Comparison of four basic models of indirect pharmacodynamic responses J. Pharmacokinet. Biopharm. 21 457 78
16. M. Miyazaki H. Mukai K. Iwanaga K. Morimoto M. Kakemi 2001 Pharmacokinetic-pharmacodynamic modelling of human insulin: validity of pharmacological availability as a substitute for extent of bioavailability J Pharm. Pharmacol. 53 1235 46
17. E. Mosekilde K.S. Jensen C. Binder S. Pramming B Thorsteinsson 1989 Modeling absorption kinetics of subcutaneous injected soluble insulin J. Pharmacokinet Biopharm. 17 67 87
18. F.Y. Liu Z. Shao D.O. Kildsig A.K. Mitra 1993 Pulmonary delivery of free and liposomal insulin Pharm. Res. 10 228 32
19. S.A. Charman D.N. [tmp] McLennan G.A. Edwards C.J. Porter 2001 Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model Pharm. Res. 18 1620 6
20. F.Y. Liu D.O. Kildsig A.K. Mitra 1992 Pulmonary biotransformation of insulin in rat and rabbit Life. Sci. 51 1683 9
21. M.C. Hsu J.P. Bai 1998 Investigation into the presence of insulin-degrading enzyme in cultured type II alveolar cells and the effects of enzyme inhibitors on pulmonary bioavailability of insulin in rats J Pharm. Pharmacol. 50 507 14
22. Brahma S.M., Singh N. Oral Delivery of Therapeutic Macromolecules: A Perspective Using the eligen technology. Drug Delivery Technology 3:(2003)
23. R.J. Schilling A.K. Mitra 1992 Pharmacodynamics of insulin following intravenous and enteral administrations of porcine-zinc insulin to rats Pharm Res. 9 1003 9
24. L. Garcia-Contreras T. Morcol S.J. Bell A.J. Hickey 2003 Evaluation of novel particles as pulmonary delivery systems for insulin in rats AAPS Pharm. Sci. 5 E9
25. A. Plum H. Agerso L. Andersen 2000 Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, in rats, dogs, and pigs, and pharmacodynamics of insulin aspart in pigs Drug Metab. Dispos. 28 155 60
26. J.R. Woodworth D.C. Howey R.R. Bowsher 1994 Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling Diabetes Care 17 64 9
27. S.A. Brown R.W. Nelson G.D. Bottoms 1987 Models for the pharmacokinetics and pharmacodynamics of insulin in alloxan-induced diabetic dogs J. Pharm. Sci. 76 295 9
28. L.B. Sheiner D.R. Stanski S. Vozeh R.D. Miller J. Ham 1979 Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine Clin. Pharmacol. Ther. 25 358 71
29. S. Lin Y.W. Chien 2002 Pharmacokinetic-pharmacodynamic modelling of insulin: comparison of indirect pharmacodynamic response with effect-compartment link models J. Pharm. Pharmacol. 54 791 800
30. R.N. Bergman 1997 New concepts in extracellular signaling for insulin action: the single gateway hypothesis Recent Prog. Horm. Res. 52 359 85 discussion 385-7
31. H. Agerso P. Vicini 2003 Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative Eur. J. Pharm. Sci. 19 141 50
32. T. Torlinska P. Mackowiak L. Nogowski K.W. Nowak E. Madry M Perz 1998 Characteristics of insulin receptor binding to various rat tissues J Physiol. Pharmacol. 49 261 70
33. S. Azhar J.C. Butte R.F. Santos C.E. Mondon G.M. Reaven 1991 Characterization of insulin receptor kinase activity and autophosphorylation in different skeletal muscle types Am. J. Physiol. 260 E1 7
34. D.J. Koerker I.R. Sweet D.G. Baskin 1990 Insulin binding to individual rat skeletal muscles Am. J. Physiol. 259 E517 23